Home Cellular health A study published in The Lancet confirms that the single injection Sputnik...

A study published in The Lancet confirms that the single injection Sputnik Light vaccine has a high safety profile and induces a strong humoral and cellular immune response in both HIV negative and HIV positive subjects.


MOSCOW, Nov. 3, 2021 / PRNewswire / – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces a new publication from the Gamaleya Center in The Lancet, one of the world’s most respected medical journals, showing shot The Sputnik Light vaccine against the coronavirus demonstrates a high safety profile and induces a strong humoral and cellular immune response. RDIF sponsored the study.

The Lancet article is available at: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00227-1/fulltext The Safety, Tolerability and Immunogenicity Study of the Sputnik Light vaccine confirmed that the vaccine induces a strong humoral and cellular immune response in both the seronegative and seropositive groups.

Most of the solicited side effects observed during the study were mild or moderate. No serious adverse event was detected.

One-shot Sputnik Light is a very effective vaccine when used both alone and as a booster. Sputnik Light has been licensed in more than 15 countries and the registration process is underway in 30 more countries.

Earlier findings from the Gamaleya Center based on data from 28,000 subjects in Moscow demonstrated that the Sputnik Light vaccine given alone has 70% effectiveness against infection with the Delta variant of the coronavirus in the first three months after vaccination. . The vaccine is 75% effective in people under 60 years of age.

The effectiveness of Sputnik Light in one shot as a booster against the Delta variant for other vaccines will be close to the effectiveness against the Delta variant of the Sputnik V vaccine: more than 83% against infection and more than 94% against l ‘hospitalization.

Sputnik Light has been shown to be more effective compared to some two-shot vaccines, which have shown a significant drop in efficacy against the Delta variant to less than 50% five months after injection. Autonomous use of Sputnik Light also offers much higher effectiveness against serious illnesses and hospitalizations.

Sputnik Light is a safe and highly effective vaccine against COVID, as confirmed by vaccination data in the real world: Argentina.

• The Paraguayan Ministry of Health estimated that Sputnik Light was 93.5% effective during the ongoing vaccination campaign in the country.

The vaccine is being tested as a booster shot in a number of clinical trials around the world. In particular, a combination of AstraZeneca / Sputnik Light exhibits higher levels of immunogenicity than the original AstraZeneca vaccine.

RDIF and the Argentine Ministry of Health are co-sponsoring the first multi-vaccine combination trial targeting 2,800 subjects (560 in each of the 5 provinces: city and province of Buenos Aires, as well as Córdoba, La Rioja and San Luis).

Interim results of the study in Argentina on heterologous treatment regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino from more than 1,000 volunteers show that Sputnik Light is an effective universal booster for these vaccines. Each combination of “vaccine cocktail” with Sputnik Light provided a higher antibody titre on day 14 after administration of the second dose compared to the original homogeneous regimens (same vaccine as the first and second dose) of each vaccine.

Data from Argentina also demonstrated a high safety profile of the use of Sputnik Light in combination with all other vaccines, with no serious side effects after vaccination, regardless of the combination.


(This story was not edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Source link